Showing: 1 - 3 of 3 RESULTS

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

For Immediate Release

Chicago, IL – October 13, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Emergent BioSolutions Inc. EBS, Vertex Pharmaceuticals Incorporated VRTX, Editas Medicine, Inc. EDIT, Cellectis S.A. CLLS and Thermo Fisher Scientific Inc. TMO.

Here are highlights from Monday’s Analyst Blog:

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

The biotech space has been booming in the past decade, with areas like gene editing stealing the show as they increase scope for treating life-threatening diseases. Gene editing or genome engineering is a process in which a DNA is inserted, modified or replaced in the genome of any living organism. In recent years, scientists have been using gene editing technology to help treat diseases with a genomic basis, like cystic fibrosis, diabetes and cancer.

CRISPR or “Clustered Regularly Interspaced Short Palindromic Repeats” is a tool primarily used to edit genes at present. Many scientists believe that this year could be a breakthrough in finding cures for cancer in DNA and investors could get familiar with terms like CRISPR and precision medicine to make the most out of advancements in this space.

Additionally, the coronavirus outbreak has pushed scientists to look for a cure through gene editing, as this novel virus keeps wreaking havoc and claiming millions of lives globally.

Disruptive Biotech Making a Mark in 2020

Cancer has been the second-leading cause of death in the United States over the past few years. Per Centers for Disease Control and Prevention (CDC) data, nearly 599,108 people lost their lives due to cancer in 2019. Gene editing has now opened up ways in which alterations in the DNA will allow patients to train their body to destroy life-threatening tumors.

Additionally, utilization of order writing techniques to rewrite infected cells and tissues, and removal of harmful mutations are also expected to boost this space. Several biotech firms are now using immuno-oncology treatments in which the immuno-oncology class of drugs teach or direct the immune system to identify cancer and then destroy it. In fact, techniques like correction within the harmful mutations, disruption of infectious agent in the DNA, or the addition of therapeutic transgenes are boosting the gene editing market.

According to Emergen Research report, the global gene editing market is projected to reach $15.79 billion by 2027 from $4.44 billion in 2019, at a CAGR of 17.2%.

One of the recent gene editing tools worth mentioning is the PAC-MAN or Prophylactic Antiviral CRISPR in human cells tool. Stanford University scientists have developed an antiviral agent against the novel coronavirus that can target and destroy specific genetic strands of the virus inside the human cell itself. The PAC-MAN which is composed of an enzyme and a strand of guide RNA has provided promising results in the laboratory when tested on human lung cells infected with SARS-CoV-2.        

2020

Fusion IV Pharmaceuticals INC Finds Functional Medicine Can Help With COVID Care

Los Angeles, CA – ( NewMediaWire ) – October 12, 2020 –  Fusion IV Pharmaceuticals INC provides functional medicine care for many patients and is focused on providing high-quality care during the Covid-19 pandemic. Their functional medicine approach has helped to identify many new treatment methods that can boost a person’s health and provide a substantial barrier to infection.

The Functional Approach Applied by Fusion IV Pharmaceutical INC

Functional medicine is a unique branch of treatments that Fusion IV Pharmaceutical INC has helped expand over the years. It focuses heavily on managing a person’s health through natural changes, such as adjusting their diet and their exercise routines.

In this way, functional medicine provides a unique opportunity to strengthen a person’s immune system against Covid-19. The worst symptoms of this disease are found to occur in those with weaker bodies or underlying conditions. Fusion IV Pharmaceutical INC seeks to help those with these problems by making their bodies more substantial and more resistant to diseases.

And Fusion IV Pharmaceutical INC has pioneered many care methods to make this process more streamlined and efficient. By understanding these techniques, those who are at more risk during this pandemic can decrease their potential risk and avoid severe symptoms.

Methods Used By Fusion IV Pharmaceuticals INC

At Fusion IV Pharmaceuticals INC, patients are being asked to follow the basic COVID prevention methods. These include social distancing – staying six feet away from others at all times – and washing and sanitizing hands whenever possible. Washing hands with soap for up to 20-30 seconds can help to kill many germs, including the COVID virus.

Fusion IV Pharmaceuticals INC is also creating dietary plans for patients that include healthy and unprocessed foods, cutting down on starches and unhealthy grains, and focusing on medicinal foods like spinach, cabbage, oranges, olives, and apples. These foods have flavonoids that help fight viruses, including kaempferol, hesperidin, and quercetin.

And Fusion IV Pharmaceuticals INC also provides immune-boosting treatments to help fight Covid and other conditions. These treatments include various types of supplements, such as 1,000-2,000 mg of Vitamin C, 20 mg of Zinc a day, 1-2 mg of sustained-released melatonin, and 1,200 mg of NAC every day. These supplements help keep the immune system functional and healthy.

Fusion IV Pharmaceuticals INC implements breakthrough techniques and delivery methods to enhance supplemental delivery. These include multiple infusion methods that work supplements directly into the bloodstream, making their delivery more comprehensive. Those who cannot tolerate this type of care may receive oral supplements that they can take at home.

About Fusion IV Pharmaceuticals INC

Fusion IV Pharmaceuticals INC is a compounding pharmacy that focuses on functional medicine, a patient-centered approach, and science-based care. Located in Los Angeles, California, they have helped promote wellness, better health, and medical science advances for over five years. They are led by Dr. Navid Vahedi, a passionate compounding pharmacist.

Source Article

Xellia Pharmaceuticals Launches New Doses of VANCO READYTM (Ready-to-use Room Temperature Premixed Vancomycin Injection Bags)

Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, is launching three new doses of VANCO READYTM, expanding its range of room temperature stable, ready-to-use (RTU) Vancomycin injection premix bags.

The VANCO READYTM availability will now cover all relevant doses from 500 mg to 2 g in 250 mg increments.

The availability of 750 mg in 150 mL, 1.25 g in 250 mL and 1.75 g in 350 mL are joining our range of presentations launched in 2019 – 500 mg in 100 mL, 1 g in 200 mL, 1.5 g in 300 mL and 2 g in 400 mL.

VANCO READYTM should not be administered during pregnancy, please see boxed warning below.

Carl-Åke Carlsson, Xellia’s CEO said: “With all seven VANCO READYTM presentations, Xellia can service the majority of needs of healthcare professionals in the vancomycin injection market. The success of our first four products has resulted in over 2,000 US institutions using VANCO READYTM. Since our announcement of approval, we have already seen strong interest and demand for the new codes from healthcare professionals on the basis of the product being room temperature and the most ready to use product available.”

Vancomycin Injection is a glycopeptide antibacterial indicated in adult and pediatric patients (1 month and older) for the treatment of septicemia (sepsis), infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections.

Craig Boyd, Xellia’s North American President said: “One of the uses for Vancomycin in the US is in the treatment of sepsis. The timely initiation of effective antibiotic treatments is universally recognized as a key intervention in the management of this life-threatening state as well as other infections. We are pleased to have been able to expand the range of doses available to clinicians, broadening their options to aid rapid and effective treatment.”

In the United States, sepsis is the third leading cause of death after heart disease and cancer, affecting more than 1.7 million people and killing more than 270,000 people within a single year1.

“Our room-temperature-stable VANCO READYTM premix has been critical in providing a truly ready Vancomycin Injection product. It aligns with recommendations from US agencies – such as the American Society of Hospital Pharmacists (ASHP), Institute for Safe Medication Practices (ISMP) and Joint Commission – to use manufacturer-prepared products as part of safe medication practice. We will continue to build on this success and focus on our ready-to-use product pipeline and partnerships during 2020.”

– Ends –

References

1 Rhee, C. et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 318, 1241–1249 (2017).

Full prescribing information for Vancomycin Injection Premix RTU can be found at www.vancoready.com and www.xellia.com/us

About Vancomycin Injection

Vancomycin Injection, Ready to use (RTU) is a proprietary formulation of vancomycin, provided as a premixed solution in single-dose flexible bags, stable at room temperature (up to 25 °C) for 16